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Previewsgenotoxic factors. In addition, the strong
correlation of ERFSs with CNVs in B cell
lymphomas strengthens the argument
that common mechanisms likely underlie
what might initially appear as distinct
phenomena and suggest that replication
arrest at ERFSs can trigger CNV forma-
tion. This is indeed likely, because similar
CNVs that mimic constitutional and
cancer-related CNVs are induced in
human and mouse cells following replica-
tion stress, including at some CFSs (Arlt
et al., 2011). It would be interesting to
similarly examine de novo CNVs in B-
lymphocytes treated to express ERFSs.
The identity of the replication and repair
factors that create the rearrangements
and the endogenous conditions or envi-
ronmental agents that lead to replica-
tion stress are unclear. These are
important questions that are being ad-dressed with regard to human germline
CNVs and translocations, and they are
equally important to understanding rear-
rangements in the cancer genome and
the risk factors involved.ACKNOWLEDGMENTS
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ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while
achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors
will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer
therapies.The B cell lymphoma/leukemia 2 (BCL-2)
family regulates critical life or death deci-
sions of cells via the mitochondrial
pathway of apoptosis (Davids and Letai,
2012). BCL-2 inhibits death by binding
the BH3 domains of pro-death BCL-2
family proteins, thus preventing mito-
chondrial outer membrane permeabiliza-
tion, which can be considered the point
of commitment to apoptosis. BCL-2 has
several anti-apoptotic cousins, including
BCL-XL, BCL-w, and MCL-1, each of
which possesses a distinct, hydrophobic
BH3-binding pocket. Lymphoid malig-
nancies are frequently addicted to BCL-
2 for their survival. Because most of these
cancers, including chronic lymphocytic
leukemia (CLL), remain incurable withconventional therapies, agents that
specifically target BCL-2 are under urgent
investigation.
Early efforts to target the BCL-2 family
were met with disappointment in the
clinic. Agents such as the antisense
oligonucleotide oblimersen sodium and
the small molecule obatoclax showed
promise as BCL-2 antagonists in pre-
clinical testing but had little clinical
activity. A potential mechanistic short-
coming of these agents is that they were
never conclusively shown to specifically
engage their purported BCL-2 family
targets in patients.
Abbott Laboratories (now AbbVie) has
developed a series of BH3-mimetic small
molecules that bind to the BH3 bind-ing sites of anti-apoptotic proteins like
BCL-2. ABT-737, which binds BCL-2,
BCL-XL, and BCL-w, was the first
molecule studied extensively preclinically
(Oltersdorf et al., 2005). Many subsequent
experiments support its killing in an on-
target fashion in cell lines, primary
human cancer cells, and animal models.
ABT-263 (navitoclax) was the first of
this series to enter the clinic. Like
ABT-737, it binds BCL-2, BCL-XL, and
BCL-w, but it has the perceived
advantage of being orally bioavailable.
Clinical activity was observed, particularly
in lymphoid cancers (Roberts et al.,
2012); however, because navitoclax
binds not only to BCL-2 but also to
BCL-XL, the drug causes predictable,February 11, 2013 ª2013 Elsevier Inc. 139
A B
Navitoclax ABT-199
BCL-2 BCL-XL
Tumor cell Platelet
BCL-2 BCL-XL
Tumor cell Platelet
Figure 1. ABT-199 Selectively Kills BCL-2-Dependent Tumor Cells
While Sparing Platelets
(A) Navitoclax (ABT-263) binds with high affinity to both BCL-2 and BCL-XL.
Because many tumors, particularly lymphoid malignancies, are addicted to
BCL-2 for survival, this potently induces tumor cell apoptosis. Platelets
depend primarily on BCL-XL for survival and, therefore, are also destroyed
by navitoclax.
(B) ABT-199 is specific for BCL-2 and induces selective death of BCL-2
dependent tumor cells while sparing platelets. Figure created by Richard
Oakley.
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Previewsdose-dependent thrombocy-
topenia (Figure 1A). This is
an on-target effect due to the
reliance of platelets on BCL-
XL for survival, and it provides
pharmacodynamic evidence
of the mechanism of action of
the drug. Indeed, drugs claim-
ing to inhibit BCL-XL that do
not cause significant throm-
bocytopenia in vivo should
be viewed with caution. The
modest clinical activity of
navitoclax is likely related to
the inability to optimize its
dose due to this dose-limiting
thrombocytopenia.
Souers et al. (2013) recently
reported the re-engineering of
navitoclax to create ABT-199,
a highly potent and selective
inhibitor of BCL-2. Through
an elegant structure-based
reverse engineering process,
ABT-199 maintains a sub-
nanomolar affinity for BCL-2but binds over three orders of magnitude
less avidly to BCL-XL, suggesting the
drug may not cause clinically significant
thrombocytopenia (Figure 1B). In an
in vitro cell culture model, the authors
provide convincing evidence that ABT-
199 selectively kills BCL-2 dependent,
but not BCL-XL dependent, cells and kills
through the mitochondrial pathway of
apoptosis. ABT-199 also potently kills
a diverse array of non-Hodgkin’s lym-
phoma (NHL) and acute myelogenous
leukemia cell lines, suggesting that the
drug has the potential to be efficacious
in a wide variety of hematologic malignan-
cies. In vivo, ABT-199 suppresses tumor
growth in several human hematologic
tumor xenograft models and shows at
least additive efficacy in combination
with chemotherapy. Importantly, the
authors also show compelling data from
both in vitro and in vivo experiments
that, as predicted, ABT-199 causes
markedly less thrombocytopenia than
navitoclax.
The true measure of a drug’s efficacy
must come from clinical trials, and the
authors provide some very preliminary
but promising data in three CLL patients.
The rapid reduction of absolute lympho-
cyte count in just 8 hr along with a
concomitant reduction in palpable lym-
phadenopathy in all three patients sug-140 Cancer Cell 23, February 11, 2013 ª2013gests that the drug is more potent
in CLL patients than navitoclax. The
lack of thrombocytopenia in this limited
data set is also a promising sign that
the preclinical studies predicting less
thrombocytopenia will be validated in
the clinic. A similar lack of thrombocyto-
penia accompanied by significant anti-
tumor activity was reported in an early
interim analysis of a phase I study of
ABT-199 in NHL patients at the 2012
American Society of Hematology Annual
Meeting. Also notable in the Souers
et al. (2013) article is that markedly
elevated LDH and phosphate levels
were seen during the same early time
frame when the anti-tumor response
was observed, reflecting significant
tumor lysis, a clinical syndrome with
potentially serious consequences if not
managed aggressively. Whether modi-
fications to the study design for future
patients are adequate to reduce the risk
of tumor lysis will be critical to the clinical
development of ABT-199.
The use of rational biomarkers has
become essential to optimizing the devel-
opment of targeted cancer therapies, and
ABT-199 is no exception. A challenge in
developing a predictive biomarker for
ABT-199 is understanding the molecular
biology underlying BCL-2 addiction. The
levels of over a dozen BCL-2 family pro-Elsevier Inc.teins, both pro- and anti-
death, fluctuate rapidly, and
protein-protein interactions
or posttranslational modifi-
cations can have a major in-
fluence on the behavior
of the system. Functional
biomarkers are one way to
probe the physiology of this
dynamic system in real time.
One such assay is BH3
profiling (Certo et al., 2006),
which measures the mito-
chondrial response to dif-
ferent BH3-only peptides,
each with its own selectivity
of interaction with anti-
apoptotic members. Results
can be used to determine
the relative dependence of a
cell on a particular anti-
apoptotic protein such as
BCL-2, BCL-XL, or MCL-1.
In many examples of primary
cancer cells and cancer cell
lines, BH3 profiling has cor-rectly predicted sensitivity to ABT-737
(Del Gaizo Moore et al., 2007; Deng
et al., 2007; Vo et al., 2012).
Central to the fate of a cancer cell
exposed to chemotherapy is its proximity
to the threshold of apoptosis, a cellular
state also detected through BH3 profiling
that is known as ‘‘mitochondrial
priming’’. Mitochondrial priming helps
explain why CLL cells are generally quite
sensitive to chemotherapy despite
having high levels of BCL-2 protein.
Most BCL-2 in primed cells is bound by
pro-death BCL-2 family members such
as BIM, thereby perching these cells
precariously near the precipice of
apoptosis. Mitochondrial priming also
provides insight into the reason why
chemotherapy may be effective against
primed malignant cells while sparing rela-
tively less primed hematopoietic stem
cells. Moreover, pretreatment priming
levels in patient samples correlate with
clinical response to cytotoxic chemo-
therapy (Davids et al., 2012; Ni Chong-
haile et al., 2011; Vo et al., 2012). Agents
like ABT-199 afford the exciting possi-
bility of selectively increasing the mito-
chondrial priming of certain cancer cells,
identified by the proper predictive
biomarker, which might then be more
effectively treated with conventional
chemotherapy.
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PreviewsClinical response to navitoclax was
strongly associated with high BIM-
MCL-1 or BIM-BCL-2 ratios, providing
evidence of the selectivity of the drug
for targeting the BCL-2 family in patients
(Roberts et al., 2012). Additional correla-
tive studies built into the ongoing clinical
trials of ABT-199 include analysis of
BCL2 gains, BCL2 amplification, as
well as BH3 profiling. These assays
have the potential to help predict the
toxicities and efficacy of ABT-199,
perhaps even one day to guide person-
alized therapy of cancer patients.
Whether ABT-199 will be most effective
as a single agent or in combination
with other agents will be important to
determine. Moreover, the biological
insights gained through correlative
studies will help inform the rational
design of combination trials to determinethe optimal role for ABT-199 in the treat-
ment of cancer.
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